Posts

Posted on

Claudia Loebel Appointed Assistant Professor at the University of Michigan

by Mahelet Asrat

Claudia Loebel, MD, PhD (Photo/Mel Evans)

The Department of Bioengineering is proud to congratulate Claudia Loebel, M.D., Ph.D. on her appointment as Assistant Professor in the Department of Materials Science and Engineering at the University of Michigan. Loebel is part of the University of Michigan’s Biological Sciences Scholar program, which recruits junior instructional faculty in major areas of biomedical investigation. Loebel’s appointment will begin in Fall 2021.

Loebel got her M.D. in 2011 from Martin-Luther University in Halle-Wittenberg, Germany and her Ph.D. in Health Sciences and Technology from ETH Zurich, Switzerland in 2016. There she worked under her advisors Professors Marcy Zenobi-Wong from ETH Zurich and David Eglin from AO Research Institute Davos. At Penn, she conducted postdoctoral research in the Polymeric Biomaterials Laboratory of Jason Burdick, Robert D. Bent Professor in Bioengineering, and as a Visiting Research Scholar in the Mauck Laboratory of the McKay Orthopaedic Research Laboratory in the Perelman School of Medicine.

Loebel was awarded a K99/R00 Pathway to Independence Award through the National Institutes of Health (NIH), which supports her remaining time as a postdoc as well as her time as an independent investigator at the University of Michigan. Loebel is excited about training the next generation of scientists and engineers and being part of their journey in becoming independent and diverse thinkers.

Loebel’s research area is inspired by the interface between material science and regenerative engineering and how it can address specific problems related to tissue development, repair, and regeneration. By developing mechanically and strucatally dynamic biomaterials, microfabrication, and matrix manipulation techniques her works aim to recreate complex cell-matrix interactions and model tissue morphogenesis and disease. The ultimate goal of her research is to use these engineered systems to develop and translate more effective therapeutic treatments for diseases such as fibrotic, inflammatory, and congenital disorders. Her lab’s work will initially focus on developing engineering lung alveolar organoids, aiming to build models of acute and chronic pulmonary diseases and for personalized medicine.

Loebel says, “I am grateful to all my Ph.D. and postdoc mentors for their continuous support and especially Jason who, over the last few years, has trained me in becoming an independent scientist and mentor. This transition would not have been possible without such a great mentor team behind me.”

Congratulations Dr. Loebel from everyone at Penn Bioengineering!

Posted on

Looking Towards the Future Through an Interdisciplinary Lens

by Erica K. Brockmeier

Yasmina Al Ghadban, a senior in the School of Engineering and Applied Science from Beirut, was able to connect her undergraduate education in bioengineering and psychology with her passion for public health through teaching, research, and extracurricular activities. Now, she is poised to leverage her “interdisciplinary lens” towards a future career in public health.

While reflecting on her undergraduate journey at Penn, senior Yasmina Al Ghadban says that she has a “ton of memories” she will take with her: lifelong friends made and skills developed through coursework, research, and teaching experiences, the chance to engage with public health communities on campus, and traveling for courses and internships. “That’s the beauty of Penn,” she says. “There’s just so many opportunities everywhere.”

As a double major in bioengineering and psychology, Al Ghadban, who is from Beirut, has certainly taken advantage of many such opportunities. Now, she is poised to leverage her “interdisciplinary lens” towards a future career in public health.

Problem-solving perspectives

Looking for a place to grow and become more independent, Al Ghadban decided to come to Penn after graduating from the International College in Lebanon. After taking an introduction to bioengineering course during her freshman year, she became enthralled by the hands-on nature of the program and enrolled in the School of Engineering and Applied Science. “I really enjoyed working with circuits and Arduino, being able to synthesize things, and I felt like being in engineering was the place where I was going to gain the most skills,” she says.

Al Ghadban is applying those skills as she completes her senior design project. She and a team of four seniors are building an autonomous robot equipped with Lidar sensors that it uses to create a map of a physical space. The team also programmed their robot to recognize high-touch surfaces that it then disinfects with UV light. “It’s a technology that is completely autonomous, cheaper than what’s on the market, and doesn’t put people at risk when they go in to disinfect,” she says. The team recently put the finishing touches on the project and presented their robot as part of a demonstration on April 14.

In addition to her degree in engineering, Al Ghadban’s interests in public and mental health spurred her to take courses and eventually pursue a double major in psychology, a field that she sees as complementary to engineering. “In psychology, we focus a lot on research and study design, research bias, and these things are similar in engineering and psychology,” she says. “Overall, I think they gave me different perspectives in terms of problem solving, and it’s nice to have that interdisciplinary lens.”

One place where Al Ghadban was able to use this interdisciplinary lens was while working as an research assistant in the Rehabilitation Robotics Lab with Michelle Johnson during her sophomore year. “The focus of the lab is to create robots for post-stroke rehabilitation, and the robotics part is very engineering-focused, but there is another part where people struggle doing the exercises,” she says. “Being able to engage with people and increasing their likelihood of doing that intervention, you rely on a lot from psychology, like interventions from positive psychology or research on how people stay engaged.”

Continue reading at Penn Today.

Posted on

Bioengineering’s Organ-on-a-chip Spin-off is Growing

Andrei Georgescu (left) and Dan Huh are the co-founders of Vivodyne, a spin-off of Huh’s BIOLines lab.

Dan Huh, Associate Professor in the Department of Bioengineering, has been steadily growing a collection of organs-on-chips. These devices incorporate human cells into precisely engineered microfluidic channels that mimic an organ’s natural environment, providing a way to conduct experiments that would not otherwise be feasible.

Huh’s previous research has involved using a placenta-on-a-chip to study which drugs are able to reach a developing fetus; investigating microgravity’s effect on the immune system by sending one of his chips to the International Space Station; and testing treatments for dry eye disease using an eye-on-a-chip, complete with a mechanical blinking eyelid.

Now, he and his colleagues are taking this technology out of their lab and into industry with their company, Vivodyne.

Andrei Georgescu, Huh’s lab-member and co-founder of Vivodyne, recently spoke with Technical.ly Philly’s Paige Gross about the growth of their company.

Research into potential drugs is usually performed first on mice, and success is only found in a fraction of humans once implemented in clinical trials, Andrei Georgescu, cofounder and CEO of Vivodyne, told Technical.ly. The genetic makeup just isn’t similar enough. But technology that allows scientists to test therapies on lab-grown human organs called “organs on chip” is allowing for testing without human subjects.

The organs on chip allow for a drug to react to tissue in a more similar way to the body than it would in a petri dish, Georgescu said. Cells sense their environment very well, he added.

“We’re making the environment more complicated, making its spacial features complicated enough to match the native complexity of the organs,” he said. “When [cells] sense a softer environment, they start to behave more realistically. Their response to the drug is more realistic.”

Continue reading “This Penn-founded biotech company specializing in human ‘organs on chip’ raised $4M” at Technical.ly Philly. 

Originally posted in Penn Engineering Today.

Posted on

Carl June Receives the Sanford Lorraine Cross Award

Carl June, MD

Carl June, MD, the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania, director of the Center for Cellular Immunotherapies at Penn’s Abramson Cancer Center, and member of the Penn Bioengineering Graduate Group, received the $1 million Sanford Lorraine Cross Award for his groundbreaking work in developing chimeric antigen receptor (CAR) T cell therapy. June is a world renowned cancer cell therapy pioneer.

“Sanford Health, the only health system in the country to award a $1 million prize for achievements in the medical sciences, announced the award on April 13 at a special ceremony in Sioux Falls, South Dakota. The biennial award recognizes life-changing breakthroughs and bringing emerging transformative medical innovations to patients.

‘This is a well-deserved and exciting award for one of Penn’s most distinguished faculty members, whose pioneering research has reshaped the fight against cancer and brought fresh hope for both adults and children with the disease,’ said J. Larry Jameson, MD, PhD, Executive Vice President of the University of Pennsylvania for the Health System and Dean of the Perelman School of Medicine. ‘His contributions truly have been transformative for patients across the globe and taken the field of oncology in new and powerful directions.'”

Read the full story in Penn Medicine News.

Posted on

Alumni Spotlight: Christopher B. Rodell

Christopher B. Rodell completed his Ph.D. in Penn Bioengineering in 2016 and has since gone on to complete a postdoc at the Center for Systems Biology at Massachusetts General Hospital and Harvard Medical School. He is now an Assistant Professor in the School of Biomedical Engineering, Science and Health Systems at Drexel University. Chris caught up with the BE Blog to talk about his love of Philly and the Penn Bioengineering community:

Chris Rodell, Ph.D.

“Yes, Penn is a great place to study – it’s full of brilliant instructors and classmates. No big surprises there. But Penn Bioengineering is so much more than that! It’s a community with passion, grit, and great times that reflect the city as a whole.

I grew up in the South, so I didn’t really know much about the school or Philly in general when I first visited. But what stood out to me was the people. From the professors to the grad students and even the other visiting students, nearly everyone I met was genuinely excited to talk about their work and just wanted to have a good time doing it. Looking back, I realize that’s exactly what I needed to thrive in a research-based education. Whether studying for a class or pulling long hours at lab, it takes some grit to make it through an engineering degree. But being passionate and having others to share your excitement with make it fun. Penn Bioengineering is a really unique place where I always felt welcome to talk with anyone – the sense of community and openness is probably one of the biggest reasons for their great success in education, research, and productive collaboration.

Through my time at Penn, I was fortunate enough to work with Jason Burdick who is, as everyone told me, ‘one of smartest and nicest people you’ll ever meet.’ I also had the opportunity to build a network of lifelong friends and mentors that span the school of engineering, the medical school, and the broader academic community of Philadelphia. These connections have continued to provide me a sense of community as I embark on an independent research career at Drexel, and I’m excited to be back in Philly!”

This post is part of BE’s Alumni Spotlight series. Read more testimonies from BE Alumni on the BE website.

Posted on

Modified Nanoparticles Can Stop Osteoarthritis Development

Zhiliang Cheng

As we age, the cushioning cartilage between our joints begins to wear down, making it harder and more painful to move. Known as osteoathritis, this extremely common condition has no known cure; if the symptoms can’t be managed, the affected joints must be surgically replaced.

Now, researchers are exploring whether their specially designed nanoparticles can deliver a new inflammation inhibitor to joints, targeting a previously overlooked enzyme called sPLA2.

Zhiliang Cheng, a research associate professor in the Department of Bioengineering, recently collaborated with members of Penn Medicine’s McKay Orthopaedic Research Laboratory, on a study of this approach, published in the journal Science Advances.

The normal function of sPLA2 is to provide lipids (fats) that promote a variety of inflammation processes. The enzyme is always present in cartilage tissue, but typically in low levels. However, when the researchers examined mouse and human cartilage taken from those with osteoarthritis, disproportionately high levels of the enzyme were discovered within the tissue’s structure and cells.

“This marked increase strongly suggests that sPLA2 plays a role in the development of osteoarthritis,” said the study’s corresponding author, Zhiliang Cheng, PhD, a research associate professor of Bioengineering. “Being able to demonstrate this showed that we were on the right track for what could be a potent target for the disease.”

The next step was for the study team – which included lead author Yulong Wei, MD, a researcher in Penn Medicine’s McKay Orthopaedic Research Laboratory – to put together a nanoparticle loaded with an sPLA2 inhibitor. This would block the activity of sPLA2 enzyme and, they believed, inflammation. These nanoparticles were mixed with animal knee cartilage in a lab, then observed as they diffused deeply into the dense cartilage tissue. As time progressed, the team saw that the nanoparticles stayed there and did not degrade significantly or disappear. This was important for the type of treatment the team envisioned.

Continue reading at Penn Medicine News.

Originally posted in Penn Engineering Today.

Posted on

“New Biosealant Can Stabilize Cartilage, Promote Healing After Injury”

New research from Robert Mauck, Mary Black Ralston Professor in Orthopaedic Surgery and Bioengineering and Director of Penn Medicine’s McKay Orthopaedic Research Laboratory, announces a “new biosealant therapy may help to stabilize injuries that cause cartilage to break down, paving the way for a future fix or – even better – begin working right away with new cells to enhance healing.” Their research was published in Advanced Healthcare Materials. The study’s lead author was Jay Patel, a former postdoctoral fellow in the McKay Lab and now Assistant Professor at Emory University and was contributed to by Claudia Loebel, a postdoctoral research in the Burdick lab and who will begin an appointment as Assistant Professor at the University of Michigan in Fall 2021. In addition, the technology detailed in this publication is at the heart of a new company (Forsagen LLC) spun out of Penn with support from the Penn Center for Innovation (PCI) Ventures Program, which will attempt to spearhead the system’s entry into the clinic. It is co-founded by both Mauck and Patel, along with study co-author Jason Burdick, Professor in Bioengineering, and Ana Peredo, a PhD student in Bioengineering.

Read the story in Penn Medicine News.

Posted on

BE Seminar: “Promoting Appendage/Limb Regeneration in Jellyfish, Drosophila, and Mouse” (Lea Goentoro)

We hope you will join us for our final seminar of the spring semester!

Speaker: Lea Goentoro, Ph.D.
Professor
Biology
California Institute of Technology

Date: Thursday, April 22, 2021
Time: 3:00-4:00 PM EDT
Zoom – check email for link or contact ksas@seas.upenn.edu

Abstract: Can limb regeneration be induced? In this talk, I will discuss our work to promote regeneration in animals with limited regeneration capacity. I will present our recent discovery of a strategy for inducing regenerative response in appendages, which works across three species that span the animal phylogeny. In Cnidaria, the frequency of appendage regeneration in the moon jellyfish Aurelia was increased by feeding with the amino acid L-leucine and the growth hormone insulin. In insects, the same strategy induced tibia regeneration in adult Drosophila. Finally, in mammals, L-leucine and sucrose administration induced digit regeneration in adult mice, including dramatically from mid-phalangeal amputation. The conserved effect of L-leucine and insulin/sugar suggests a key role for energetic parameters in regeneration induction. The simplicity by which nutrient supplementation can induce appendage regeneration provides a testable hypothesis across animals.

Lea Goentoro Bio: Lea Goentoro is a Professor of Biology in the Division of Biology and Biological Engineering at the California Institute of Technology. She holds a B.S. in Chemical Engineering from University of Wisconsin, Madison and a Ph.D. in Chemical Engineering from Princeton University. Prior to joining Caltech, she did postdoctoral training in the Department of Systems Biology at Harvard Medical School. Her work has been supported by the Damon-Runyon Cancer Foundation, the James S. McDonnell Foundation, the National Science Foundation, and the National Institute of Health.

Posted on

Ning Jenny Jiang Appointed Associate Professor in Penn Bioengineering

Jenny Jiang, Ph.D.

We are thrilled to announce the appointment of Ning Jenny Jiang, Ph.D. as the tenured Peter & Geri Skirkanich Associate Professor of Innovation in the Department of Bioengineering at the University of Pennsylvania. Dr. Jenny Jiang comes to Penn from the Department of Biomedical Engineering at the University of Texas at Austin. She obtained her Ph.D. from Georgia Institute of Technology and did her postdoctoral training at Stanford University.

Jiang’s research focuses on systems immunology by developing technologies that enable high-throughput, high-content, single cell profiling of T cells in health and disease and she is recognized as one of the leading authorities in systems immunology and immunoengineering. She is a pioneer in developing tools in biophysics, genomics, immunology, and informatics and applying them to study systems immunology in human diseases. Her early work on the development of the first high-throughput immune-repertoire sequencing technology opened up a brand new field of immune-repertoire profiling. Her laboratory developed the first high-throughput in situ T cell receptor affinity measurement technology and she pioneered the development of integrated single T cell profiling technologies. These technological innovations have changed the paradigm of T cell profiling in disease diagnosis and in immune engineering for therapeutics. Using these technologies, her laboratory has made many discoveries in immunology, from unexpected infants’ immunity in malaria infection to “holes” in T cell repertoire in aging immune systems in elderly, from dysregulated T cells in HIV infection to high-throughput identification of neoantigen-specific T cell receptor for cancer immunotherapy.

Dr. Jiang was also recently elected to the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows for her outstanding contributions to the field of systems immunology and immunoengineering and devotion to the success of women in engineering. A virtual induction ceremony was held on March 26, 2021.

Additionally, Jiang is a recipient of numerous other awards, including the Damon Runyon-Rachleff Innovation Award, an NSF CAREER award, and a Chan Zuckerberg Initiative Neurodegeneration Challenge Network Ben Barres Early Career Acceleration Award. She was selected as one of National Academy of Medicine Emerging Leaders in Health and Medicine Scholars in 2019.

Jiang’s appointment will begin June 1, 2021. Welcome to Penn Bioengineering, Dr. Jiang!

N.B.: Edited 7/2/21 with full endowed chair title.

Posted on

Michael Mitchell on Keeping mRNA Vaccines Viable

A National Institute of Allergy and Infectious Diseases lab freezer used for COVID-19 vaccine research. Both of the current mRNA-based COVID vaccines require ultra-cold freezers to prevent their mRNA from degrading, spurring research into other ways to stabilize the molecule.

As the technology behind two of the COVID-19 vaccines, Messenger RNA (mRNA) is having a moment. A single-stranded counterpart to DNA, mRNA translates its genetic code into proteins; by injecting mRNA engineered to produce proteins found on the exterior of the virus, the vaccine can train a person’s immune system to recognize the real thing without making them sick.

However, because mRNA is a relatively unstable molecule, distributing these vaccines involves extra logistical challenges. Doses must be transported and stored at ultra-cold temperatures to make sure the mRNA inside doesn’t degrade and lose the genetic information it carries.

Michael Mitchell
Michael Mitchell

As mRNA vaccines and other therapies take off, researchers are looking for other ways to forestall this degradation. One of them is Michael J. Mitchell, Skirkanich Assistant Professor of Innovation in the Department of Bioengineering, who is studying the use of lipid nanoparticles to encapsulate and protect mRNA on its way into the cell. That sort of packaging would be particularly beneficial in proposed mRNA therapies for certain genetic disorders, which aim to deliver the correct protein-making instructions to specific organs, or even a fetus in utero.

But for stabilizing mRNA for vaccine distribution, many other strategies are being explored. In “Keeping covid vaccines cold isn’t easy. These ideas could help,” Wudan Yan of MIT Technology Review reached out to Mitchell for insight on LIONs, or lipid inorganic nanoparticles. These nanoparticles work the opposite way of Mitchell’s organic ones, with the mRNA stabilized by binding to their exteriors.

Continue reading at MIT Technology Review.

Originally posted in Penn Engineering Today.